So I wonder if the deal with Bintai Kinden is dead now. If they aren't going to pay for the trials in the US, maybe Generex is just going to go with the data they get out of China to try to get approval in the US. If it's not BK and they can't get money from Barda or some other grants/deals etc, I can't see them paying for a US trial with dilution. I won't be on the call but I hope they make it crystal clear as to what's happening with the BK deal.
I'm not worried about giving up patent rights to the Covid vaccine in China. I just hope whatever protocol they have to follow in China for these trials doesn't drag this out too long.
Generex Biotechnology Corp. (GNBT) Stock Research Links